Loading...
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
Mohd Sharial, M S N Crown, J Hennessy, B T
Mohd Sharial, M S N
Crown, J
Hennessy, B T
Citations
Altmetric:
Advisors
Editors
Other Contributors
Date
2012-12
Date Submitted
Keywords
Other Subjects
Subject Mesh
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Breast Neoplasms
Cell Proliferation
Drug Resistance, Neoplasm
Female
Humans
Immunosuppressive Agents
Phosphatidylinositol 3-Kinase
Proto-Oncogene Proteins c-akt
Receptor, erbB-2
Signal Transduction
Sirolimus
TOR Serine-Threonine Kinases
Antineoplastic Agents
Breast Neoplasms
Cell Proliferation
Drug Resistance, Neoplasm
Female
Humans
Immunosuppressive Agents
Phosphatidylinositol 3-Kinase
Proto-Oncogene Proteins c-akt
Receptor, erbB-2
Signal Transduction
Sirolimus
TOR Serine-Threonine Kinases
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
mds200.pdf
Adobe PDF, 215.7 KB
Alternative Titles
Publisher
Abstract
Approximately 15%-23% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), which leads to the activation of signaling pathways that stimulate cell proliferation and survival. HER2-targeted therapy has substantially improved outcomes in patients with HER2-positive breast cancer. However, both de novo and acquired resistance are observed.
Language
en
ISSN
1569-8041
eISSN
ISBN
DOI
10.1093/annonc/mds200
PMID
22865781